These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15359148)

  • 21. Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.
    Magee TV; Ripp SL; Li B; Buzon RA; Chupak L; Dougherty TJ; Finegan SM; Girard D; Hagen AE; Falcone MJ; Farley KA; Granskog K; Hardink JR; Huband MD; Kamicker BJ; Kaneko T; Knickerbocker MJ; Liras JL; Marra A; Medina I; Nguyen TT; Noe MC; Obach RS; O'Donnell JP; Penzien JB; Reilly UD; Schafer JR; Shen Y; Stone GG; Strelevitz TJ; Sun J; Tait-Kamradt A; Vaz AD; Whipple DA; Widlicka DW; Wishka DG; Wolkowski JP; Flanagan ME
    J Med Chem; 2009 Dec; 52(23):7446-57. PubMed ID: 19775168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
    Calbo E; Garau J
    Respiration; 2005; 72(6):561-71. PubMed ID: 16354997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy of ketolides in the treatment of respiratory tract infections.
    Reinert RR
    J Antimicrob Chemother; 2004 Jun; 53(6):918-27. PubMed ID: 15117934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
    Fogarty CM; Buchanan P; Aubier M; Baz M; van Rensburg D; Rangaraju M; Nusrat R
    Int J Infect Dis; 2006 Mar; 10(2):136-47. PubMed ID: 16183318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PROTEKT years 1-3 (1999-2002): study design and methodology.
    Harding I; Felmingham D
    J Chemother; 2004 Dec; 16 Suppl 6():9-18. PubMed ID: 15690682
    [No Abstract]   [Full Text] [Related]  

  • 27. The evolution of antimicrobial agents used for the management of CARTIs: a focus on a new class of antimicrobials--the ketolides.
    Sbarbaro JA
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S389-99. PubMed ID: 15603248
    [No Abstract]   [Full Text] [Related]  

  • 28. Introduction to PROTEkT: years 1-3 (1999-2002).
    Harding I
    J Chemother; 2004 Dec; 16 Suppl 6():5-7. PubMed ID: 15690681
    [No Abstract]   [Full Text] [Related]  

  • 29. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000).
    Reinert RR; Rodloff AC; Halle E; Baer W; Beyreiss B; Seifert H; Wichelhaus TA; Maass M; Mehl M
    Chemotherapy; 2004 Jun; 50(3):143-51. PubMed ID: 15272227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telithromycin--a ketolide antibiotic for the treatment of outpatients with community-acquired respiratory tract infections.
    Counts M
    Clin Nurse Spec; 2005; 19(3):121-3. PubMed ID: 15897765
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of new antibacterial therapies in at-risk populations.
    Lorenz J
    J Infect; 2002 Feb; 44 Suppl A():25-30. PubMed ID: 12150492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamic rationale for short-duration antibacterial therapy.
    Nicolau DP
    J Infect; 2002 Feb; 44 Suppl A():17-23. PubMed ID: 12150491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Management of community-acquired lower respiratory infections. Management in the hospital].
    Chidiac C
    Rev Mal Respir; 1999 Jan; 16 Suppl 3():S11-2. PubMed ID: 10088221
    [No Abstract]   [Full Text] [Related]  

  • 35. Primary care challenges in the management of respiratory tract infections.
    JAAPA; 2006 Sep; Suppl():4-14; quiz 15-6. PubMed ID: 17001773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macrolide-resistant Streptococcus pneumoniae: clinical implications for the empiric treatment of community-acquired respiratory tract infections.
    Brunton S; Iannini P
    MedGenMed; 2005 Dec; 7(4):63. PubMed ID: 16614685
    [No Abstract]   [Full Text] [Related]  

  • 37. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections.
    Low DE; Felmingham D; Brown SD; Rangaraju M; Nusrat R
    J Infect; 2004 Aug; 49(2):115-25. PubMed ID: 15236918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
    Brixner DI
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S400-7. PubMed ID: 15603249
    [No Abstract]   [Full Text] [Related]  

  • 39. Will resistance to ketolides develop in Streptococcus pneumoniae?
    Leclercq R
    J Infect; 2002 Feb; 44 Suppl A():11-6. PubMed ID: 12150490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.
    Lonks JR; Goldmann DA
    Clin Infect Dis; 2005 Jun; 40(11):1657-64. PubMed ID: 15889365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.